New combo therapy aims to keep myeloma at bay after transplant

NCT ID NCT02253316

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 17 times

Summary

This study tests a three-drug combination (ixazomib, lenalidomide, and dexamethasone) given after a stem cell transplant to people with multiple myeloma. The goal is to see if this treatment can keep the cancer away longer. After four cycles, participants receive one of two maintenance drugs to continue controlling the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope

    Duarte, California, 91010, United States

  • Colorado Blood Cancer Institute

    Denver, Colorado, 80218, United States

  • Emory University - Winship Cancer Institute

    Atlanta, Georgia, 30322, United States

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

  • Tennessee Oncology, PLLC

    Nashville, Tennessee, 37203, United States

  • University of California, San Francisco

    San Francisco, California, 94143, United States

  • Washington University School of Medicine

    St Louis, Missouri, 62864, United States

Conditions

Explore the condition pages connected to this study.